Biological effect of azacitidine (CC-486) on diffuse large B-cell lymphoma

Biomarker study for a phase 1, Open-Label, multicenter trial of azacitidine (CC-486) plus R-CHOP in subjects with high-risk previously untreated diffuse large B-cell lymphoma Overall design: RNA and DNA methylation profiles of DLBCL tissue samples and CD3+ circulating cells methylation profiles pre and post CC486 treatment were generated by Illumina sequencing. *Please note that authors has not provided the 'pre and post CC486 treatment' status for each Sample record.